Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Celldex Therapeutics, Inc. or Bio-Techne Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Celldex Therapeutics, Inc. and Bio-Techne Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Celldex Therapeutics, Inc. and Bio-Techne Corporation

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Latest Biotechnology and Celldex Therapeutics, Inc., Bio-Techne Corporation Stock News

As of July 31, 2026, Celldex Therapeutics, Inc. had a $3.0 billion market capitalization, compared to the Biotechnology median of $252.6 million. Celldex Therapeutics, Inc.’s stock is up 40.1% in 2026, up 7.9% in the previous five trading days and up 66.86% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $0.9 million with a % net profit margin. As of July 31, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.352 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

As of July 31, 2026, Bio-Techne Corporation had a $11.2 billion market cap, putting it in the 79th percentile of all stocks. Bio-Techne Corporation’s stock is up 22.6% in 2026, up 0.7% in the previous five trading days and up 24.94% in the past year.

Currently, Bio-Techne Corporation’s price-earnings ratio is 103.7. Bio-Techne Corporation’s trailing 12-month revenue is $1.2 billion with a 9.0% net profit margin. Year-over-year quarterly sales growth most recently was -1.5%. Analysts expect adjusted earnings to reach $1.918 per share for the current fiscal year. Bio-Techne Corporation currently has a 0.4% dividend yield.

How We Compare Celldex Therapeutics, Inc. and Bio-Techne Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Celldex Therapeutics, Inc. and Bio-Techne Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Celldex Therapeutics, Inc. and Bio-Techne Corporation Growth Grades

Company	Ticker	Growth
Celldex Therapeutics, Inc.	CLDX	F
Bio-Techne Corporation	TECH	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Celldex Therapeutics, Inc. has a Growth Score of 3, which is Very Weak. Bio-Techne Corporation has a Growth Score of 89, which is Very Strong.

The Growth Grade Winner: Bio-Techne Corporation

As you can clearly see from the Growth Grade breakdown above, Bio-Techne Corporation has a more attractive growth grade than Celldex Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Bio-Techne Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Celldex Therapeutics, Inc. and Bio-Techne Corporation’s Quality Grades

Company	Ticker	Quality
Celldex Therapeutics, Inc.	CLDX	F
Bio-Techne Corporation	TECH	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Celldex Therapeutics, Inc. has a Quality Score of 19, which is Very Weak. Bio-Techne Corporation has a Quality Score of 98, which is Very Strong.

The Quality Grade Winner: Bio-Techne Corporation

As you can clearly see from the Quality Grade breakdown above, Bio-Techne Corporation has a better overall quality grade than Celldex Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Bio-Techne Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Celldex Therapeutics, Inc. and Bio-Techne Corporation’s Momentum Grades

Company	Ticker	Momentum
Celldex Therapeutics, Inc.	CLDX	A
Bio-Techne Corporation	TECH	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Celldex Therapeutics, Inc. has a Momentum Score of 84, which is Very Strong. Bio-Techne Corporation has a Momentum Score of 79, which is Strong.

The Momentum Grade Winner: Celldex Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Celldex Therapeutics, Inc. is considered to have stronger momentum compared to Bio-Techne Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Celldex Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Celldex Therapeutics, Inc. and Bio-Techne Corporation Grades

In addition to Momentum, Quality and Growth, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Celldex Therapeutics, Inc. and Bio-Techne Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Celldex Therapeutics, Inc. or Bio-Techne Corporation Stock?

Overall, Celldex Therapeutics, Inc. stock has a Growth Score of 3, Momentum Score of 84 and Quality Score of 19.

Bio-Techne Corporation stock has a Growth Score of 89, Momentum Score of 79 and Quality Score of 98.

Comparing Celldex Therapeutics, Inc. and Bio-Techne Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.